FDA declines linvoseltamab decision for RRMM due to facility issue
The U.S. Food and Drug Administration (FDA) has rejected Regeneron Pharmaceuticals’ application for approval of linvoseltamab to treat adults with relapsed or refractory…
Margarida Maia, PhD, science writer — 
Articles by Margarida Maia
Phase 3 trial of CAR T-cell therapy anito-cel for RRMM opens
Kite Pharma has initiated iMMagine-3, a global Phase 3 clinical trial that’s set to test anitocabtagene autoleucel (anito-cel), an investigational CAR T-cell therapy, against…
First-line induction therapy with Sarclisa delays myeloma progression
Adding Sarclisa (isatuximab) to standard induction therapy for transplant-eligible people with newly diagnosed multiple myeloma extends the time patients live without their disease…
Blenrep combinations for myeloma now under review in EU
A committee of the European Medicines Agency (EMA) has accepted for review GSK’s marketing authorization application for Blenrep (belantamab mafodotin) to be used as…
MMRF invests $1M to advance DCT’s new CAR T-cell therapy
Through its Myeloma Investment Fund, the Multiple Myeloma Research Foundation (MMRF) has invested $1 million in novel CAR T-cell technology from Dynamic Cell Therapies…
First RR multiple myeloma patient treated with ABBV-383
A Phase 3 clinical trial evaluating the safety and efficacy of AbbVie’s experimental therapy ABBV-383 in adults with relapsed or refractory multiple…
FDA committee votes 12-0 for myeloma trial outcome measure
A unanimous vote by a committee of the U.S. Food and Drug Administration (FDA) could lead to an early outcome measure — one known as…
Elrexfio now approved in Canada as recurring myeloma treatment
Health Canada has granted conditional approval to Pfizer’s Elrexfio (elranatamab-bcmm), expanding the list of countries where the medication can be used for adults with…
Abecma wins CHMP’s thumbs up for use in earlier treatment lines
Bristol Myers Squibb has received a positive opinion from an arm of the European Medicines Agency (EMA) on the use of its CAR T-cell…
AstraZeneca to add CAR T-cell therapy to pipeline with Gracell buy
AstraZeneca is set to buy Gracell Biotechnologies in a deal worth up to $1.2 billion that would add GC012F — an experimental dual-targeting…